{"id":"late-haart","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Immune reconstitution inflammatory syndrome (IRIS)"}]},"_chembl":{"chemblId":"CHEMBL1830815","moleculeType":"Small molecule","molecularWeight":"358.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HAART (Highly Active Antiretroviral Therapy) typically combines drugs from different classes—such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase inhibitors—to achieve potent and durable HIV suppression. The term 'Late HAART' suggests initiation of therapy at a later stage of HIV infection, though the mechanism remains suppression of viral replication across multiple enzymatic targets.","oneSentence":"Late HAART is a combination antiretroviral therapy regimen that suppresses HIV replication by inhibiting multiple stages of the viral life cycle.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:33:48.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (initiated at advanced or late-stage disease)"}]},"trialDetails":[{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT01511237","phase":"PHASE3","title":"Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2011-12","conditions":"HIV Infections","enrollment":379},{"nctId":"NCT04165200","phase":"NA","title":"Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2018-09-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT01455688","phase":"PHASE4","title":"Early Antiviral Therapy for Critically Ill HIV Infected Patients","status":"COMPLETED","sponsor":"Hospital Nossa Senhora da Conceicao","startDate":"2012-01-01","conditions":"HIV Infection","enrollment":115},{"nctId":"NCT01044810","phase":"","title":"Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-01","conditions":"Treatment Failure, HIV or AIDS, CD4 Cell Counts","enrollment":559}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Late HAART","genericName":"Late HAART","companyName":"Hospital Nossa Senhora da Conceicao","companyId":"hospital-nossa-senhora-da-conceicao","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Late HAART is a treatment approach for HIV infections that involves starting antiretroviral therapy when the disease is more advanced, often characterized by low CD4 cell counts. Late HAART typically involves the use of small molecule antiretroviral drugs such as nevirapine, zidovudine, and lamivudine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}